A 38-year-old man with a 2-year history of Meniere disease (left ear) is referred for management. He has had 4–5 vertiginous episodes per month, each lasting 30–45 minutes, with progressive hearing loss. He reports severe impact on his work as a software engineer. Audiometry confirms low-frequency sensorineural hearing loss. MRI with gadolinium shows no retrocochlear pathology. He has failed conservative management with salt restriction and diuretics for 6 months. What is the most appropriate next step in management?

Explanation

## Management of Refractory Meniere Disease ### Clinical Context **Key Point:** This patient has failed first-line medical therapy (salt restriction, diuretics) for 6 months with persistent, frequent episodes affecting quality of life. He is a candidate for second-line intervention. ### Treatment Algorithm for Meniere Disease ```mermaid flowchart TD A["Meniere Disease Diagnosis"]:::outcome --> B{"First-line therapy<br/>Salt restriction +<br/>diuretics × 3–6 months"}:::decision B -->|"Symptom control achieved"| C["Continue medical therapy"]:::action B -->|"Inadequate response"| D{"Hearing preservation<br/>critical?"}:::decision D -->|"Yes"| E["Intratympanic gentamicin<br/>or corticosteroids"]:::action D -->|"No or hearing<br/>already poor"| F["Surgical options:<br/>Labyrinthectomy or<br/>vestibular neurectomy"]:::action E --> G{"Response to<br/>intratympanic therapy?"}:::decision G -->|"Good"| H["Continue monitoring"]:::outcome G -->|"Poor"| F ``` ### Why Intratympanic Gentamicin? | Aspect | Intratympanic Gentamicin | Labyrinthectomy | Vestibular Neurectomy | |--------|--------------------------|-----------------|----------------------| | **Hearing preservation** | Good (ototoxic risk ~10–15%) | Poor (destroys hearing) | Excellent | | **Vertigo control** | 70–80% | 90–95% | 90–95% | | **Invasiveness** | Minimal (office procedure) | Surgical | Surgical | | **Reversibility** | Partial | No | No | | **Best for** | Hearing preservation priority | Hearing already lost | Hearing preservation + vertigo control | **High-Yield:** Intratympanic gentamicin is the **preferred second-line agent** when hearing preservation is a priority. It works by selectively ablating vestibular hair cells (vestibulotoxicity) while preserving cochlear function in most cases. ### Mechanism of Intratympanic Gentamicin 1. Gentamicin diffuses across the round window membrane into perilymph 2. Preferentially accumulates in vestibular dark cells and hair cells 3. Causes irreversible ablation of vestibular function 4. Cochlear hair cells are relatively spared (ototoxicity risk ~10–15%) 5. Results in chemical labyrinthectomy without hearing loss in most patients ### Dosing & Administration **Clinical Pearl:** Gentamicin 26.7 mg/mL (0.4 mL) is injected transtympanically via a small myringotomy. Typically given as: - Single injection or - Weekly injections × 3–4 weeks - Patient kept supine 30 min post-injection for round window contact ### Why NOT Labyrinthectomy? **Warning:** Labyrinthectomy is destructive and causes permanent hearing loss. It is reserved for patients with: - Severe, intractable vertigo - Hearing already non-functional (unilateral) - Failed intratympanic therapy This patient still has measurable hearing and is early in the disease course — hearing preservation is paramount. ### Why NOT Repeat MRI? **Key Point:** The initial MRI with gadolinium has already excluded retrocochlear pathology (acoustic neuroma, MS). Repeat imaging is not indicated unless clinical features change. ### Why NOT Vestibular Rehabilitation Alone? **Clinical Pearl:** VRT is adjunctive for balance compensation but does NOT treat the underlying endolymphatic hydrops or reduce vertigo frequency. It is insufficient as monotherapy for refractory Meniere disease. ### Mnemonic: GENT **Mnemonic:** **G**entamicin **E**ndolymphatic **N**ecrosis **T**herapy — intratympanic gentamicin selectively destroys vestibular function while preserving hearing [cite:Dhingra ENT 8e Ch 12]